Skip to content

Is NAD+ Therapy Worth It? An Evidence-Based Buyer Guide

What NAD+ studies show, how treatment costs compare, and the plan and refund terms to check before paying for IV therapy or injections.

By Marcus HaleLongevity Research Editor
Updated

6 min read · 13 sources

On this page

For routine energy, focus or healthy-aging goals, current evidence does not establish that paying for NAD+ IV therapy or injections produces a worthwhile health benefit. Oral NAD+ precursors have more human research, but raising a blood biomarker is different from improving a symptom, preventing illness or extending life. A useful decision starts with the outcome you want, the evidence for that exact product and the complete cost.

This guide separates those questions. Our provider comparison lists affiliate partners first and may earn us commissions. A provider's position, price or prescription process does not establish that NAD+ treatment works.

Affiliate partner

RxSpan MD

Physician-led NAD+ & longevity telehealth

See RxSpan MD

What the human studies can tell you

NAD+ supports normal cellular metabolism, and changes in NAD-related pathways are part of aging research. Those biological observations do not establish that every tired person has a treatable NAD+ deficiency 12.

Trials of oral NMN and NR show that blood NAD-related measurements can increase 34. Findings for outcomes people notice are less consistent. An older-adult muscle study found biochemical changes without corresponding improvement in muscle performance 5. A small trial in people with mild cognitive impairment did not demonstrate a cognitive benefit 6. A review of metabolic-syndrome studies also found a mixed clinical picture 7. Different populations, doses and endpoints limit what any one trial predicts for an individual.

For a buyer, the question is therefore specific: has the proposed route and formulation improved the outcome you care about in a relevant human trial? A study of oral NR cannot establish that an injected NAD+ product improves energy. Read NAD+ vs NMN vs NR before treating those products as equivalents.

Evidence and value

  • Oral precursors and NAD-related biomarkersStrong evidence

    Human trials show changes in blood NAD-related measurements.

  • IV tolerability and short-term observationsWeak evidence

    Small studies describe infusion experience; they do not establish routine wellness benefit.

  • Established value for routine wellness infusionsNone evidence

    The evidence does not establish that commercial IV programs deliver the advertised health benefits.

A biomarker response, a tolerability observation and an improvement in health are different findings.

IV evidence has grown, but remains preliminary

The 2019 infusion pilot examined changes in plasma and urine metabolites during a six-hour NAD+ infusion. It was not a test of durable improvements in energy, cognition or longevity 8.

A 2026 retrospective study compared NAD+ and NR infusions in a commercial wellness setting. It reported differences in infusion time and tolerability, with short-term biomarker follow-up. Its observational design and authors' employment by the clinic operator matter when interpreting the results 13. These findings do not establish that either infusion improves routine wellness or outperforms oral supplementation.

It would be inaccurate to say that only one human IV study exists. It would also be inaccurate to describe newer tolerability observations as proof of meaningful health benefits. Our IV evidence review and Niagen IV comparison explain the distinction.

Symptoms and medical conditions need a separate assessment

Persistent fatigue, problems concentrating or difficulty recovering deserve an assessment of their possible causes. A commercial NAD+ test or a biological explanation does not by itself identify the cause of those symptoms or demonstrate that an infusion is appropriate.

Reports involving substance-use treatment are sometimes presented as the strongest reason to try NAD+. The cited reports are uncontrolled case series involving broader treatment programs, including combined interventions 910. They cannot isolate the effect of NAD+ or establish that a person has a clinically important NAD+ deficit.

Evidence-based addiction care has treatments supported by controlled research and systematic reviews 1112. NAD+ should not replace or delay that care. The reports do not justify a general recommendation to buy NAD+ as an adjunct either; any proposed experimental addition needs discussion with the treating clinician. Similar caution applies to claims about post-illness fatigue: a plausible mechanism is not a validated reason to spend money on a particular commercial program.

Work out the complete cost before comparing offers

Ask for a written quote that identifies the route, formulation, medication quantity, supply duration, amount due now and future charges. IV appointments, home prescriptions and oral supplements buy different services. A lower headline number does not necessarily mean a lower total cost or better value. Restore Hyper Wellness, for example, uses studio-specific quotes for appointment-based care; a national brand name does not establish a national price.

The NAD+ price index carries current provider figures and their check dates. Use the therapy cost calculator with the actual quote rather than a promotional rate alone.

An introductory price is not a renewal price

Embody's review separates its introductory and recurring rates and describes conflicting cancellation instructions. Luvo's current offer also distinguishes its first delivery from later four-week charges. Budget from the renewal terms, then account for any genuine introductory discount separately.

Wellorithm’s payment structure also needs the total commitment read alongside its headline rate. Check whether an offer can be paid monthly or requires a prepaid or financed term.

A monthly average may require prepayment

MadeMed's plans require a quarterly or six-month payment and a CMP blood test. Bodybuilding Health+ offers different term selections, with a prepaid total on the selected longer plan. A monthly equivalent does not mean you can cancel after one month and recover the balance.

Mondae’s monthly and quarterly plans, TrueMe and Vytora Health also have plan choices that need their actual payment terms read. Compare amount due, quantity and cancellation rights rather than ranking their monthly labels alone. Current pricing could not be reconfirmed for Magnolia; an older figure should not be treated as a current quote.

Shorter billing cycles change the annual budget

A charge every 28 days occurs 13 times per 52 weeks. Goldspan's review explains that distinction. Bayan's billing cycle is also shorter than a calendar month, while Rehydra+ lists several supply-duration options. Do not multiply every advertised rate by twelve.

A starting figure can leave important details unresolved

CoreAge's starting-price guide explains why a floor is not a complete quote. MyDrHank and Nex Gen likewise need their published qualifiers preserved. For NEUVÉ, ask which route, membership and testing charges apply to the actual prescription.

Where a page contradicts another page, get the proposed terms in writing. Nova, Alinwell’s conflicting price displays and AHBARx’s supply and route questions illustrate why reading a single price tile can be insufficient. Similar-looking payment pages, such as those previously observed for Believe Health and Longevixx, do not by themselves establish shared ownership or equivalent clinical care.

The formulation and the policy need separate checks

A troche, patch, nasal spray and injection are different products. Try Ageless’s compounded troche review explains its formulation, while our Gentle Patches ingredient review addresses why an NAD+ label does not establish that a patch contains NAD+ or delivers it through skin. Neither format should inherit evidence from an oral NR trial.

For home prescriptions, Care Bare Rx’s plan review and EdgeRx’s nasal-spray review help separate the advertised offer from the details to confirm before paying. He & She MD’s pharmacy disclosures are a separate question from evidence that the treatment works.

Published inclusions are part of the comparison

Read the actual program rather than assuming every quoted rate includes the same services. Oak’s NAD+ pricing and inclusions and Obu Health’s program review describe their public offers. Nolu’s supply and billing questions show why the amount of medication still matters beside a recurring charge.

Check what happens if you stop or are not approved

Canceling a future renewal is different from obtaining a refund for an order already reviewed, prescribed or sent to a pharmacy. CoreAge's refund terms and Sprout's review describe consultation-fee limitations. Direct Meds and Strut have processing cutoffs that matter before shipment.

Ask when payment is collected, which fees remain if treatment is declined, how to cancel and whether unused prepaid supplies can be refunded. A satisfaction statement on a homepage should be read alongside the written policy. Lighter You’s conflicting public prices and policies and Superior Remedies’ cancellation and availability conflicts are examples where a written clarification is useful. Also confirm the actual pharmacy, clinical support and state eligibility. A name in a general pharmacy network is not proof that it prepares your NAD+ prescription.

Before paying

Five questions for the proposed program

  • Which specific outcome is this intended to improve?
  • What human evidence applies to this route and formulation?
  • What is due now, and when do later charges occur?
  • Which fees or prepaid amounts remain if treatment stops?
  • Who will reassess progress and answer clinical concerns?
An assessment and a prescription do not substitute for evidence of benefit.

A practical way to decide

A defensible purchase needs a clear goal, evidence relevant to the proposed product, a complete quote and a plan to reassess. Current NAD+ wellness evidence leaves substantial uncertainty about benefit. Spending more for a faster delivery route does not resolve that uncertainty.

If the expected benefit cannot be explained, the cost is uncomfortable or the terms remain unclear, there is a reasonable basis to defer the purchase. For medical symptoms, pursue an appropriate clinical assessment. If you still want to compare commercial options, use our provider reviews alongside the research library, with their different roles kept clear.

Frequently asked questions

Is NAD+ therapy worth the money?

Current evidence does not establish that routine NAD+ wellness infusions or injections deliver a worthwhile health benefit. Oral precursor studies more often measure NAD-related biomarkers than dependable improvements in symptoms. Compare evidence, the complete payment commitment and the intended outcome before deciding.

Who has been shown to benefit from NAD+ therapy?

Different studies test different products and populations, so there is no single proven beneficiary group for commercial NAD+ wellness programs. Uncontrolled addiction-treatment reports cannot establish a specific NAD+ benefit or a treatable deficit. Medical symptoms warrant an appropriate assessment rather than an assumption of NAD+ deficiency.

Does NAD+ IV therapy work better than oral supplements?

Current research does not establish superior health outcomes from commercial IV NAD+ treatment. A 2019 metabolite study and a 2026 retrospective infusion comparison address narrower questions than durable improvements in energy, cognition or longevity.

Should NAD+ replace addiction treatment?

No. Evidence-based addiction care has treatments supported by controlled research. Small uncontrolled reports involving NAD+ and other interventions cannot justify replacing or delaying that care, or a general recommendation to buy NAD+ as an adjunct.

References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
  2. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. https://pubmed.ncbi.nlm.nih.gov/22848760/
  3. Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. https://pubmed.ncbi.nlm.nih.gov/36482258/
  4. Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/29599478/
  5. Elhassan YS, Kluckova K, Fletcher RS, et al. (2019). Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports. https://pubmed.ncbi.nlm.nih.gov/31412242/
  6. Orr ME, Kotkowski E, Ramirez P, et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. https://pubmed.ncbi.nlm.nih.gov/37994989/
  7. Oliveira-Cruz A, Macedo-Silva A, Silva-Lima D, et al. (2024). Effects of Supplementation with NAD+ Precursors on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research. https://pubmed.ncbi.nlm.nih.gov/39111741/
  8. Grant R, Berg J, Mestayer R, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. https://pubmed.ncbi.nlm.nih.gov/31572171/
  9. Blum K, McLaughlin T, Lewandrowski KU, et al. (2024). Complex NADASE Infusions Improve Clinical Outcome in Substance Use Disorder: Descriptive Annotation in Fifty Cases. Journal of Addiction Psychiatry. https://pubmed.ncbi.nlm.nih.gov/39949994/
  10. Blum K, Han D, Baron D, et al. (2022). Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases. Current Psychiatry Research and Reviews. https://pubmed.ncbi.nlm.nih.gov/36118157/
  11. Mattick RP, Breen C, Kimber J, Davoli M (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/24500948/
  12. McPheeters M, O'Connor EA, Riley S, et al. (2023). Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. https://pubmed.ncbi.nlm.nih.gov/37934220/
  13. Reyna K, et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging. https://pubmed.ncbi.nlm.nih.gov/41704678/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.